To read the full story
Related Article
- Maintain Funding for COVID Pill beyond April: Academic Societies to Govt
February 13, 2024
- Academic Societies to Urge Govt to Continue Funding for COVID Pills beyond April
February 5, 2024
- Health Ministry Panel OKs Inclusion of 5-in-1 Jab in NIP from Next April
December 21, 2023
- MHLW Panel OKs 5-Year Extension of Pneumovax Transitional Measure
January 11, 2019
- MHLW Panel to Discuss Changing Current Transitional Period for Pneumococcal Vaccinations in Elderly
November 2, 2018
- MHLW Presents Schedule for Discussions on Inclusion of 6 Vaccines in Public Vaccination Programs
May 21, 2018
- MHLW to Start Discussions on Pneumovax Vaccination in Post-Transition Period
September 15, 2017
REGULATORY
- MHLW Asks for Ramp Up of HPV Vaccines after 5-Fold Rise in Demand
October 11, 2024
- MHLW Orders Label Revision for Systemic NSAIDs
October 11, 2024
- Xocova to Face CEA Price Cuts on Poor Cost Performance vs. SOC
October 10, 2024
- Kisunla to Follow Same Rules as Leqembi in Pricing and Post-Launch Review
October 10, 2024
- Supply of Anapeine Generic to Start by Year-End: Minister
October 9, 2024
It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…